The bill creates the plant-based medicine policy review panel
(policy review panel). The purpose of the policy review panel is to study the use of plant-based medicines to support mental health. The policy review panel operates for one year. The policy review panel shall submit a report on its findings and policy recommendations to the house of representatives public and behavioral health and human services
committee and the senate health and human services committee, or any successor committees; the governor; and the department of human services.
The bill defines plant-based medicine as a naturally occurring
hallucinogenic plant-based compound. Forms of plant-based medicine only include psilocybin, psilocyn, dimethyltryptamine, and ibogaine.
